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HIV-1 Vpr N-terminal tagging 
affects alternative splicing of the 
viral genome
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Eva Claeys1, Wim Trypsteen2, Linos Vandekerckhove2, Sven Eyckerman3,4, Kris Gevaert3,4 & 
Bruno Verhasselt1
To facilitate studies on Vpr function in replicating HIV-1, we aimed to tag the protein in an infectious 
virus. First we showed that N-, but not C-terminal HA/FLAG tagging of Vpr protein preserves Vpr 
cytopathicity. Cloning the tags into proviral DNA however ablated viral production and replication. By 
construction of additional viral variants we could show this defect was not protein- but RNA-dependent 
and sequence specific, and characterized by oversplicing of the genomic RNA. Simulation of genomic 
RNA folding suggested that introduction of the tag sequence induced an alternative folding structure in 
a region enriched in splice sites and splicing regulatory sequences. In silico predictions identified the HA/
His6-Vpr tagging in HIV-1 to affect mRNA folding less than HA/FLAG-Vpr tagging. In vitro infectivity and 
mRNA splice pattern improved but did not reach wild-type values. Thus, sequence-specific insertions 
may interfere with mRNA splicing, possibly due to altered RNA folding. Our results point to the 
complexity of viral RNA genome sequence interactions. This should be taken into consideration when 
designing viral manipulation strategies, for both research as for biological interventions.
Vpr is a pleiotropic accessory HIV-1 protein, that enhances infection of resting cells, modulates both HIV and cel-
lular transcription, along with induction of G2 arrest and cell death (reviewed by Kogan1). Although Vpr is dispen-
sable for in vitro infection and replication, in vivo studies have shown that infection with Vpr-deleted or mutated 
HIV/SIV strains are less deleterious to the host2. These mutated strains tend to revert to full Vpr function3, 
which is reflected by high sequence conservation of the protein over viral isolates4. Given the small genome, 
HIV-1 maximizes its genetic coding potential by using three reading frames and alternative splicing5. Three types 
of mRNA are expressed: multiple spliced (coding for Tat, Rev and Nef protein), singly spliced (Env, Vif, Vpu and 
Vpr) and unspliced transcripts (Gag, Pol and the viral genome). Splicing occurs when the intronic sequence 
between a 5′ splice donor (5′ ss) and a 3′ splice acceptor (3′ ss) is excised by the spliceosome6. The recognition of 
these splice sites is regulated mainly by the intrinsic strength of the splice site, and can be influenced by the pres-
ence of polypyrimidine tracts (PPTs) and branch site sequences. Additionally, the virus encodes cis-acting exonic 
and intronic silencers/enhancers that affect splicing7 and typically mutations within these sequences can impact 
viral replication8–10. However, it is becoming clear that not only the sequence of splicing elements can influence 
the splicing process but also local RNA structures, modulating binding of spliceosome elements and splice site 
usage11–13.
HIV-1’s small genome also implies dependency on cellular host proteins and machinery for viral replication: 
HIV proteins need to interact with cellular proteins to exert their function14. Here, we designed a strategy to iden-
tify and evaluate host proteins interacting with Vpr, to study its regulation and function. Protein tagging facilitates 
pull-down, to screen for and identify protein-protein interactions using mass spectrometry15. A dual-tagged Vpr 
fusion protein approach was chosen, allowing for tandem affinity purification, which has the benefit of reducing 
non-specific interactions16. While fusion proteins have the advantage that the antibody for pull-down does not 
need to target bait protein epitopes possibly shielded by interaction partners, tagging of proteins can affect their 
function17. Hence, initially the function of amino- (N) versus carboxy- (C) terminal tagged Vpr was compared. 
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Subsequently, tagged Vpr in a replicating HIV-1 was constructed to provide a tool to study protein function in an 
infectious cycle at biologically relevant protein levels. Our experiments provide new experimental insights not 
only on HIV-1 viral protein tagging strategies but also on the biology of HIV-1 mRNA splicing.
Results
Vpr N-terminal, but not C-terminal, tagging preserves cytopathic function. To reduce possible 
steric hindrance on protein function, the use of small tags is recommended18. We therefore chose a FLAG/HA 
tandem tag to tag Vpr as a fusion protein. Single glutamine linkers (Q residue) were added between the tags and 
Vpr to further improve stability and bioactivity of the fusion protein19.
First, we determined whether N- or C-terminal tagging of Vpr was most appropriate to preserve cytopathicity, 
defined by a combination of cytotoxic and cytostatic activity. For this, tagged Vpr was cloned into a retroviral 
vector that allows for expression from a bicistronic mRNA also encoding dNGFR using a PCR strategy as shown 
in Fig. 1a. The resulting construct was transfected in 293T cells to assess Vpr induced G2 cell cycle arrest and 
survival. As shown in Fig. 1b, N-terminal tagging (HA/FLAG-VPR) conserved cell cycle arrest induction com-
parable to that by the wild-type (WT) Vpr while the C-terminal tagged Vpr (VPR-FLAG/HA) lost this property. 
We also observed that only N-terminal tagging preserves the cytopathic functions of Vpr: in Fig. 1c, the fraction 
of dNGFR marker expressing SupT1 cells over time is presented, as an indirect assessment of Vpr’s cytopathic 
effect. While Vpr expressing cells regressed throughout culture, control transduced cells grew continuously. The 
phenotype of HA/FLAG-Vpr resembles that of the WT protein, unlike C-terminal Vpr-FLAG/HA transduced 
Figure 1. N/C Tagged Vpr cloning and functional testing. (a) Molecular cloning strategy for N/C-terminal 
tagging to Vpr. FWD N and REV C primers have non-binding tails containing the HA and FLAG tags. More 
detailed methodology can be found in Supplement 1, together with primer sequences. In the final LZRS 
retroviral vector constructs, the wild-type Vpr or Vpr tagged fusion proteins (either HA/FLAG-Vpr (N-terminal 
tags) or Vpr-FLAG/HA (C-terminal tags)) are cloned and expressed from a bicistronic mRNA (IRES sequence) 
also encoding dNGFR as a separate marker protein to identify construct expressing cells. Both tagged proteins 
are preceded by Met-Glu (ME) and HA, FLAG and Vpr are separated by single Gln (Q) linkers. Numbers 
indicate amino acid position of Vpr (black), and number of amino acids added by tagging (grey). (b) Cell cycle 
analysis on pLZRS-transfected 293T cells, representative of one of three experiments. 48 h post-transfection, 
cells were harvested, sorted for dNGFR expression, RNase A treated and stained with propidium iodide for 
cellular DNA content. Control samples were either untransfected (Mock) or transfected with a control LZRS 
vector (ctr). Data were analyzed with the FlowJo cell cycle analysis platform, applying the Dean-Jett-Fox model. 
Separate green curves in the shaded histogram illustrate the fraction of cells in G1, S and G2 phase of the cell 
cycle. The percentage of cells in G2 phase (represented by green curve covering highest DNA content) is shown 
for each sample. (c) Absolute number of dNGFR marker positive SupT1 cells, in cultures after 2 (D2), 4 (D4 or 
7 (D7) days after transduction with LZRS retroviral particles. Three different Vpr constructs were transduced as 
indicated, or a control LZRS vector was used (ctr).
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cells, exhibiting slightly reduced growth. Together, we conclude from these data that only N-terminal tagging of 
Vpr preserves cytopathic function. In the scope of this study, we therefore selected N-terminal HA/FLAG-Vpr 
tagging strategy to be applied in HIV-1.
HIV-1 Vpr HA/FLAG N-terminal tagging abrogates viral production and replication. To create 
the HIV-1 HA/FLAG-Vpr construct, an overlap extension PCR was applied to incorporate tags, as described in 
Supplement 1. The resulting construct is shown in Fig. 2a.
To ensure efficient and stable expression of the HA/FLAG-Vpr fusion protein, a Met-Glu amino acid doublet 
was positioned upstream of the tag, since we found this conserved doublet to be important for post-translational 
stability of Vpr (unpublished data). Since Vif and Vpr share a 60 base-pairs overlap, inserting the tags accordingly 
results in an insertion in Vif what could affect function. To exclude this potential bias, infection experiments 
were done in cells (293T and SupT1) permissive for HIV lacking functional Vif 20. Unexpectedly, when using 
this proviral construct to produce virions, viral production was nearly ablated (Fig. 2b). Expression of the virus 
encoded marker gene (HSA) from the HSA-IRES-nef reading frame was not reduced (Fig 2c), indicating transfec-
tion of proviral plasmid was efficient. The HA/FLAG-Vpr fusion protein could be demonstrated on Western blot 
(Fig. 2d). The viruses produced were strongly affected in replication in SupT1 cells, as shown in Fig. 2e, using the 
HSA marker to quantify infection. This reduced replication was confirmed in CEM-GFP reporter cells, encoding 
a GFP marker protein in response to LTR transcriptional activity, thus a different cell line and a different reading 
of viral expression (Supplement 2).
Effect of Vpr N terminus insertions is RNA based and sequence specific. To rule out that these 
observations were due to a particular property of the HIV-1 HSA-IRES-Nef reporter virus, the tags were cloned 
into a WT HIV-1 backbone (Supplement 3). We could reproduce the inhibition of viral production, confirming 
that the inserted tags sequence cause impaired viral production and replication even in a WT virus not modified 
to express a marker gene.
Next, we assessed if other, smaller insertions at the same position could have the same outcome and whether 
reading frames are involved. Therefore, we first inserted either a 20 or 21 base-pair long insert in the N-terminus of 
Vpr (VPRins20 and VPRins21 constructs respectively, Fig. 2f; cloning is described in Supplement 1), similar but shorter 
compared to the modification by HA/FLAG-Vpr tagging (60 basepairs). Only a N-terminal fragment of the original 
HA insertion of 21 or 20 bp length was inserted, so respectively conserving or shifting the Vif and Vpr reading frame.
We found that both constructs did not affect viral production nor infection (Supplement 4), thus disruption of 
the corresponding protein domains did not explain the observation and shorter insertions are insufficient to affect 
viral fitness. Next we asked whether changes in the local sequence was sufficient to induce viral defects. To test this, 
a 60 bp scrambled sequence replacing the WT sequence (VPRscr, Fig. 2g; cloning is described in Supplement 1) 
was cloned into the Vif/Vpr overlap. We preserved the start codon of Vpr and ruled out the introduction of stop 
codons. Similar to VPRins20 or VPRins21, both viral production and infection were unaffected. (Supplement 4).
Together, from these mutants we conclude that the effect of Vpr N terminus insertions is not due to alterations 
in Vpr or Vif protein, and sequence specific.
Viral defects following Vpr N terminus insertions correlate with oversplicing. Since reduced viral 
production could be caused by oversplicing of genomic RNA8,9, we measured the expression levels of the major 
HIV-1 mRNA species by quantitative PCR (RT-qPCR) (Fig. 3a). We used primer sets to measure either unspliced 
(US), singly spliced (SS) and multiple spliced (MS) mRNA and one primer set to quantify total HIV-1 RNA. 
Results were expressed relative to WT values as described in Materials and Methods. We found significantly less 
US and SS mRNA expressed from HIV-1 HA/FLAG-Vpr, together with less Nef-2 expression (MS). We verified 
that the total HIV-1 RNA expression (also determined by transfection efficiency) was not affected (Fig. 3b), by 
comparing expression values of total HIV-1 RNA between untagged (WT) and HA/FLAG-Vpr. We compared the 
splicing in the VPRins20, VPRins21 and VPRscr mutants and found, in accordance with unaffected viral production 
and infection, no difference compared to WT (Supplement 5). In conclusion, the observed defect of the HA/
FLAG-Vpr correlates to altered mRNA splicing. This oversplicing of RNA will result in relatively reduced levels 
of Gag/Pol/Env major structural proteins, which is probably the underlying mechanism for the inability of this 
mutant virus to produce viral progeny5. Of note, the HSA marker is expressed from MS mRNA, explaining why 
this expression is not reduced in the 293T cells transfected with proviral HIV-1 HA/FLAG-Vpr (Fig. 2c).
Vpr N terminus insertions that affect splicing alter RNA folding simulation. To explore the cause 
of oversplicing in the HA/FLAG-Vpr mutant, we first checked the integrity of known splice donor and accep-
tor sites, and of known splicing regulatory sequences7 and found these not to be affected by inserting the tags. 
Subsequently, we analyzed whether the mRNA folding could be affected. We compared folding of all mutant 
constructs with the WT virus. We used the Genebee web-based platform21 to simulate the folding of the HIV-1 
genomic sequence. Due to size limits of the RNA secondary structure prediction algorithm, 8 kb genomic frag-
ments of the HIV-1 NL4-3 strain were sequentially included in the algorithm to identify the differentially folded 
genomic region. Finally, as shown in Fig. 3c, we simulated the p5041–9017 region (WT numbering), encoding 
Vif-Env, and found that the HA/FLAG-Vpr folding but not that of the other VPR mutants deviated significantly 
from that of the WT sequence in the genomic region p5000–7000, a region rich in splice sites and splicing regu-
latory elements22. Comparative predictions of the full HIV-1 genome folding with the PPfold3.1 bioinformatics 
tool23 confirmed this observation (Fig. 3d). Together, these data suggest that mRNA folding is affected by the 
inserted tag, which could cause skewed viral mRNA splicing and the resulting block in viral production.
HA/His6-Vpr as a functional alternative. Besides HA and FLAG, other small tags such as Myc, His6 and 
V5 are successfully used for tandem affinity purification. In order to find a functional substitute for HA/FLAG 
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Figure 2. pNL4-3 HIV-1 HA/FLAG-Vpr cloning and functional testing. (a) Representation of HIV-1 reading 
frames 1 (Vif) and 3 (Vpr) showing the overlap. The zoomed detail displays the composition of the Vpr protein 
N-terminus, containing HA and FLAG tags, preceded by Met-Glu (ME), and separated by single Gln (Q) linkers. 
Numbers indicate amino acid position of Vpr (black), and number of amino acids added by tagging (grey)  
(b) Reverse Transcriptase (RT) activity of 293T-produced virus. 48 h post-transfection, viral supernatant was 
harvested and quantified for RT activity. N = 14, Mann-Whitney U test, p < 0.0001. (c) HSA expression of pNL4-3 
HIV-1 HA/FLAG-Vpr plasmid transfected 293T cells measured by flow cytometry after staining with an APC 
labelled antibody, 48 h post-transfection as marker of transfection efficiency. Dot plots show HSA-APC staining 
versus side scatter (SSC). Numbers indicate percentage of cells staining positively. (d) Western blot for HA and 
FLAG expression of pNL4-3 HIV-1 WT or HA/FLAG-Vpr transfected 293T cells, 48 h post-transfection, β -actin 
was stained as loading control. (e) SupT1 infection, quantified by HSA expression measured by flow cytometry on 
different time points post-infection (D1 to D7 as indicated). Cells were infected with 40 ng p24 WT virus or, due 
to defective viral production, 100 μ l HA/FLAG-Vpr viral supernatant. At day 7 post-infection WT infected cells 
had succumbed. Numbers indicate percentage of cells staining positively. (f) Representation of the VPRins20 and 
VPRins21 mutant in the HIV-1 reading frames 1 (Vif) and 3 (Vpr). The overlap of both reading frames is shown, as 
well as 20 or 21 bp inserted from HA. Numbers indicate amino acid position of Vpr (black), and number of amino 
acids added by the insert (grey), in the case of VPRins20 the frame shift induced does not allow to count amino acids 
added (g) Simplified representation of the VPRscr mutant in the HIV-1 reading frames 1 (Vif) and 3 (Vpr). The 
overlap of both reading frames is replaced with a scrambled sequence, but without losing the ATG start codon or 
without introducing premature stop codons. Numbers indicate amino acid position of the artificial protein (black).
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Figure 3. HIV-1 HA/FLAG-Vpr splicing and mRNA folding. (a) Splicing assay on mRNA, isolated from 293T 
cells, 48 h post-transfection with pNL4-3 HIV-1 WT or HIV-1 HA/FLAG-Vpr plasmids. This mRNA was reverse 
transcribed into cDNA and used as input material, together with primers p1–10, described in Supplement 7. 
Graph shows expression of unspliced (US), singly spliced (SS) and multiple spliced (MS) mRNAs relative to 
WT levels, normalized for reference gene expression and corrected for total HIV-1 RNA. Error bars indicate the 
standard error of the mean (SEM). Wilcoxon signed-rank test, N = 8, p = 0.007813 (p1 + 2), 0.007813 (p5 + 6), 
0.007813 (p3 + 8), 0.007813 (p2 + 8), 0.007813 (p3 + 9), 0.4609 (p7 + 9). (b) Ratio of average Cq values of duplo 
PCR reactions (non-normalized data) obtained using total HIV-1 mRNA primers p1 + p10 and UBC FWD/REV 
primer set, N = 7 on cDNA from total cellular RNA of 293T cells transfected with pNL4-3 WT or HA/FLAG-Vpr 
plasmids, Mann-Whitney U test, p = 0,1282. (c) In silico mRNA folding predictions of NL4-3 HIV-1 WT or  
HA/FLAG-Vpr genomic region p5041–9017, using Genebee RNA secondary structure prediction algorithm. 
The circle specifies the region where predicted folding is altered, numbers indicate the position in the NL4-3 
genome, starting from the 5′ LTR sequence. (d) In silico predictions of full NL4-3 HIV-1 WT or HA/FLAG-Vpr 
genome mRNA folding structure, using PPfold3.1 bioinformatics tool. The rectangle zoom-out and arrows 
specify the region where predicted folding is altered.
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tandem tagged Vpr, we explored a variety of combinations including orientations with these five small tags via 
simulations with the Genebee platform.
We found the HIV-1 HA/His6-Vpr virus (tags shown in Fig. 4a) to be the most valid option, with a predicted 
RNA folding structure (Fig. 4b,c) most resembling the WT architecture. Next we looked more specifically at the 
stem structures in region p5000–6500 in the NL4-3 plasmid, encompassing 3′ ss A2, A3, A4a-b-c, A5 and 5′ ss 
D3 (Fig. 4d). Remarkably, it appears that the 5′ ss D3 was captured in a stem structure with HA in both HA/
FLAG-Vpr and HA/His6-Vpr virus. Also, supplementary stem structures were introduced between 3′ ss A4c-a-b 
Figure 4. HIV-1 HA/His6-Vpr as a valid alternative. (a) Strategy used to construct HA/His6-Vpr starting 
from sequence verified gBlocks® . This was cloned in the pNL4-3 HIV HSA plasmid using the previously 
described cloning strategy (Supplement 1). Numbers indicate amino acid position of Vpr (black), and 
number of amino acids added by tagging (grey). (b) In silico mRNA folding predictions of NL4-3 HIV-1 HA/
His6-Vpr genomic region p5041–9017, using Genebee RNA secondary structure prediction algorithm. The 
circle specifies the region where predicted folding is altered, compared to the WT NL4-3 HIV-1 predicted 
folding, numbers indicate the position in the NL4-3 genome, starting from the 5′ LTR sequence. (c) In silico 
predictions of full HIV-1 HA/His6-Vpr genome mRNA folding structure, using PPfold3.1 bioinformatics tool. 
The rectangle zoom-out and arrows specify the region where predicted folding is altered. (d) In silico mRNA 
folding predictions of NL4-3 HIV-1 WT, HIV-1 HA/FLAG-Vpr and HIV-1 HA/His6-Vpr genomic region 
p5000–6500 (or extended with tags length), using Genebee. Location of 5′ and 3′ ss is indicated as green dots, 
based on7. The position of the inserted tags within the constructs is highlighted with a blue line. (e) Western blot 
for HA and His6 expression of pNL4-3 WT HIV-1 or pNL4-3 HIV-1 HA/His6-Vpr plasmid transfected 293T 
cells, 48h post-transfection. 10 μ g of protein was loaded and β -actin was stained as loading control. (f) Splicing 
of mRNA, isolated from 293T cells, 48 h post-transfection with pNL4-3 WT HIV-1 or pNL4-3 HIV-1 HA/
His6-Vpr plasmids, as described in Fig. 3a. Graph shows expression of unspliced (US), singly spliced (SS) and 
multiple spliced (MS) mRNA relative to WT levels, normalized for reference gene expression and corrected for 
total HIV-1 RNA. Error bars indicate the standard error of the mean (SEM).Wilcoxon signed-rank test, N = 6, 
p = 0.2188 (p2 + 4), 0.1563 (p5 + 6), 0.03125 (p3 + 8), 0.0625 (p2 + 8), 0.03125 (p3 + 9), 0.09375 (p7 + 9).
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that could affect splicing to these sites. Additionally, in both tagged constructs, the relative orientation of 3′ ss 
A3 and 5′ ss D4 appears to have changed in this model. These latter changes are however different between both 
constructs, suggesting splicing profiles may differ.
Confirming the folding predictions, functional tests indeed showed that viral production was not affected 
(Supplement 3) and also expression of the tags could be demonstrated (Fig. 4e). Merely, a modest effect on viral 
splicing was seen (Fig. 4f), characterized by decreased Vpu/Env and Nef transcript expression compared to 
untagged WT virus.
Viral titration infection on SupT1 cells (Fig. 5a and Supplement 6) showed reduced infectivity and replication 
of HIV-1 HA/His6-Vpr compared to the untagged WT virus, however to a lesser degree than the reduction seen 
with HIV-1 HA/FLAG-Vpr (compare to Fig. 2c). Upon adding higher amounts of input virus, efficient replication 
was initiated. These infection data are in line with the decreased amounts of Env and Nef transcripts, most likely 
responsible for reduced infectivity of the progeny virus.
To further characterize the functionality of the HIV-1 HA/His6-Vpr, we monitored both cytotoxic and cyto-
static functions of Vpr. We found that, when sufficient infection levels were reached, cell death could be induced 
by replicating HA/His6-Vpr virus (Fig. 5b). VSV-G pseudotyping accelerated infection and Vpr cytopathicity 
(Fig. 5c). This would allow for single round infection in cells non-permissive for Vif deleted viruses. Cell cycle 
analysis of transfected 293T cells (Fig. 5d) confirms that N-terminal tagging does not affect the cytostatic function 
of Vpr. As a control in this cell cycle experiments, HIV-1 Δ Vpr (HIV-1 HSA-IRES-Nef with stop codons in all 3 
reading frames in the N-terminus of Vpr, after the N-terminal overlap with the Vif reading frame), not express-
ing Vpr was used24. Together, these data show the HIV-1 HA/His6-Vpr can be used to study Vpr function in the 
context of a replication competent virus.
Figure 5. HIV-1 HA/His6-Vpr functional testing. (a) Replication curves of HIV-1 HA/His6-Vpr and WT 
HIV-1 after infection of SupT1 with 5–160 ng p24. Infection is measured by HSA expression, at several days 
post-infection (p.i.). WT replication is presented as solid lines; HA/His6-Vpr as dashed lines. (b) Increased viral 
input infection experiment in SupT1, using 160 ng p24 HIV-1 HA/His6-Vpr to monitor induction of cell death. 
Upper dot plots show forward (FSC) and side scatter (SSC), lower plots show HSA staining versus SSC for cells 
gated in the live scatter gate shown in the upper dot plots. Figures indicate percentage of cells staining positively 
with the APC labelled antibody. (c) SupT1 infection with VSV-G pseudotyped HA/His6-Vpr virus, 160 ng p24 
virus. Upper dot plots show forward (FSC) and side scatter (SSC), lower plots show HSA staining versus SSC 
for cells gated in the live scatter gate shown in the upper dot plots. Figures indicate percentage of cells staining 
positively with the APC labelled antibody, gated on live cells as shown. (d) Cell cycle analysis on pNL4-3-
transfected 293T cells 48 h post-transfection. 293T cells were transfected with the proviral constructs or Mock 
transfected, as indicated. Data were analyzed with the FlowJo cell cycle analysis platform on flow cytometry data 
of DNA staining, applying the Dean-Jett-Fox model. Left panel: histograms from a representative experiment. 
Separate green curves in the shaded histogram illustrate the fraction of cells in G1, S and G2 phase of the cell 
cycle. The percentage of cells in G2 phase (represented by green curve covering highest DNA content) is shown 
for each sample. Right panel: percentage of cells in G2 phase induced by the indicated constructs or Mock 
transfection. Error bars indicate standard deviation. Mann-Whitney U test comparing samples. N = 8 (Mock), 
N = 6 (HIV WT/HIV Δ Vpr) or N = 5 (HIV HA/Flag-His6-Vpr). Mock-HIV WT p = 0.0007, Mock-HIV Δ Vpr 
p = 0.0062, HIV WT–HIV Δ Vpr p = 0.0303, HIV Δ Vpr-HIV HA/FLAG-Vpr p = 0.0159, HIV Δ Vpr-HIV HA/
His6-Vpr p = 0.0317.
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Discussion
We present the detrimental effect of HA/FLAG-Vpr tagging on viral production and infection, correlating with 
viral mRNA oversplicing. As a functional alternative, we developed the HIV-1 HA/His6-Vpr virus to be used in 
Vpr interaction studies when the use of replication competent virus is preferred over the use of single protein 
overexpression.
We started this study by comparing N- versus C-terminal tagging of Vpr for preservation of the cytopathicity 
by Vpr. Both strategies have their drawbacks for tagging, given the known domain-function relationships of the 
termini25. N-terminal modification might impede Vpr’s nuclear localization/import and infection of non-dividing 
cells26 or transactivation of transcription27. G2 arrest on the other hand, is mediated by the C-terminal α -helical 
domain25, although hydrophobic residues in the first N-terminal α -helix are also required to induce cell cycle 
arrest28. The cell death inducing domains of Vpr appear to be more dispersed throughout the protein and func-
tionally depend on nuclear localization, but not on G2 arrest25.
In this study we found that C-terminal, but not N-terminal tagging, affected cytopathic function of Vpr. 
Therefore, the N-terminus of Vpr was tagged in HIV-1. Inevitably, introduction of N-terminal tags to Vpr within 
HIV-1 also modifies the C-terminus of Vif. This has no effect on infection in permissive SupT1 cells, as these do 
not require Vif expression to counteract APOBEC3G restriction20.
The ablated viral production and replication in both SupT1 and CEM CD4+ T cell lines observed with HIV-1 
HA/FLAG-Vpr, was associated with a significant reduction in US and SS mRNA, characteristic for oversplicing. 
Madsen and Stoltzfus8,9 reported that oversplicing of HIV-1 genomic mRNA impedes viral production. Their 
studies show that mutational regulation of downstream 5′ splice donor site strength, or that of the exonic splicing 
silencer ESSV, can enhance the usage of suboptimal upstream 3′ splice acceptor sites A1 or A2, resulting in over-
splicing and defective replication. The integrity of known splice sites and regulatory sequences7 is not affected by 
insertion of the HA/FLAG tags. Moreover, the reduction on viral production we observe is much more dramatic 
than that described in these and other studies8,9,13,29.
In our study, additional mutants produced to assess the genotype-phenotype correlation (either a N-terminal 
fragment of the original HA tag of 21 or 21 bp length inserted, or a 60 bp scrambled region at the same site to 
replace the wild-type sequence) did not show oversplicing nor defects in viral production, infection or replica-
tion. From these results we could conclude that the observed phenotype of HIV-1 HA/FLAG-Vpr was not due to 
disturbance of the Vif or Vpr reading frames and to be sequence specific.
We propose that an aberrant RNA folding structure is underlying the observed phenotype. Indeed, studies 
in eukaryotes have demonstrated the importance of mRNA folding in regulating primary transcript splicing. 
Secondary mRNA structures can inhibit or promote binding of spliceosomal elements to the pre-mRNA, or can 
bring important sequences into closer proximity to enhance efficiency of splicing (reviewed in30). Also in viruses, 
like the Duck hepatitis B virus31 or Rous sarcoma virus32, well-structured RNA sequences have been described 
that suppress splicing. In adenovirus, an intronic hairpin structure approximates crucial splice sites to improve 
splicing efficiency33. HIV-1 mutational and phylogenetic studies have similarly demonstrated the existence of 
local secondary mRNA structures and their importance for HIV-1 genomic mRNA splicing34,35. This balanced 
expression of unspliced and singly/multiple spliced mRNA is in turn decisive for efficient HIV-1 replication, as 
we and others demonstrate8,9.
Unlike local RNA structures, HIV-1 long range RNA-RNA interactions and higher order, tertiary structures 
are less well documented, and biological data on this matter are lacking. There is some in vitro evidence for the 
existence of a long range pseudoknot in the 5′ -untranslated and Matrix coding regions of HIV-1 genomic RNA36, 
as confirmed via the SHAPE (selective 2′ -hydroxyl acylation analyzed by primer extension)-based study on the 
architecture of the full NL4-3 HIV-1 RNA genome37. An in silico study by Assis38, demonstrated the covariance 
of single nucleotide mutations in HIV-1 evolution, what suggests a strong epistatic selection of the HIV-1 tertiary 
structure. Also more recently, a comparative model for the higher order structure of the HIV-1 genome was 
published by Süküsd and colleagues39, revealing a conserved core domain, formed by a set of long distance inter-
actions with a particular high frequency of compensatory base changes.
Our in silico results suggest that the aberrant viral production and replication, observed after N-terminal 
tagging of Vpr, is likely due to an effect on tertiary mRNA folding of the HIV-1 transcripts. However, one should 
bear in mind that mRNA folding simulates only folding potentials, making it difficult to assess structure-function 
correlations.
Nevertheless, the structural impact of the insertions were experimentally shown to be sequence specific: sim-
ulation showed that aberrant nucleotide bridging arose between the inserted HA/FLAG-Vpr tags and both up/
downstream mRNA sequences changed folding. Mutants VPRins20, VPRins21 and VPRscr support the validity of 
the simulations as their predicted structures fitted more with the WT structure and no functional defects could 
be observed.
As an alternative for tagging we propose the HA/His6-Vpr virus. This does not have the same simulated fold-
ing alterations as the HA/FLAG-Vpr virus, yet still showed more moderate disturbed splicing, with reduced Env/
Vpu and Nef mRNA expression levels. The latter can explain the reduced infection rate observed, since both Env 
and Nef expression are known to enhance viral infectivity40. Still, HIV-1 HA/His6-Vpr is suitable for studies on 
Vpr function in a replicating virus. Published studies with tagged Vpr in HIV-1 replication generally express Vpr 
in trans, limiting the replication to a single round of infection. Yet a limited number of studies describe the intro-
duction of single Vpr protein tags HA or FLAG in the proviral DNA41,42. Unfortunately these studies do not assess 
the impact of this tagging on viral production, infectivity and resulting fitness.
Understanding the dynamics and interactions of HIV-1 mRNA is important to further decipher the virus and 
might aid to develop new therapeutic strategies. This knowledge could be applied to target and modify mRNA 
folding/splicing of HIV-1. Indeed, previous studies demonstrated the power of controlling HIV-1 alternative 
splicing and multiplication using antisense derivatives of U7 small nuclear RNA43 or small molecules IDC16 and 
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8-Azaguanine44,45. Similarly, ABX464 – a small molecule inhibiting Rev-mediated export of US RNA – is able 
to compromise HIV-1 replication in a humanized mouse model which now awaits confirmation in a Phase IIa 
clinical trial46.
It is becoming more and more clear that conservation of the tertiary structure of HIV-1 is important for effi-
cient viral biogenesis. This offers new therapeutic possibilities, aiming to support current therapy regimens. As 
the mRNA folding is encoded within the viral genetic code, in vitro manipulations of highly conserved regions 
can therefore interfere with proper genomic folding. This should be considered when tagging proteins for inter-
action studies.
Materials and Methods
Molecular cloning pLZRS and pNL4-3 constructs. Full experimental details are described in 
Supplement 1
Cell culture. Human embryonic kidney 293T (DZSM, Braunschweig, Germany), Phoenix-Amphotropic 
packaging (Phoenix A) cells (kind gift from Dr. P. Achacoso and Dr. G.P. Nolan, Stanford University School of 
Medicine, Stanford, CA)47 and SupT1 (AIDS Research and Reference Reagent Program, National Institutes of 
Health, Bethesda, MD) were cultured at 37 °C in a 7% CO2 (vol/vol) humidified atmosphere, in IMDM com-
plete medium (IMDMc): Iscove’s modified Dulbecco’s medium (Life Technologies, Merelbeke, Belgium) sup-
plemented with 10% (vol/vol) fetal bovine serum (FBS; Hyclone, Thermofisher Scientific, Waltham, MA) and 
2 mM L-glutamine (Life Technologies). CEM-GFP cells were obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH (originating from Dr. Jacques Corbeil, Infectious Diseases Research Center 
Quebec48) and cultured at 37 °C in a 5% CO2 (vol/vol) humidified atmosphere, in RPMI 1640 medium with 10% 
(vol/vol) FBS and 2 mM L-glutamine.
Cell cycle analysis. Nuclear DNA content was assessed in 293T according to the protocol of Wen and col-
leagues49. Before jetPEI® DNA transfection, 293T cells were seeded at 4 × 105 cells/4 ml IMDM complete (con-
taining 10% (vol/vol) FBS, 100 U/mL penicillin and 100 g/mL streptomycin (both from Life Technologies)) in 6 
well cell culture plates (Corning, New York, NY). The next day, 4 μ g plasmids were transfected to the producer 
cells as instructed by supplier (Polyplus, New York). 48 h post-transfection, cells were detached and analyzed for 
DNA content: 2 × 105 cells were suspended in 200 μ l PBS and 200 μ l cell cycle staining buffer (see ref. 49) and 
incubated at 37 °C for 20 min. Transfection efficiency was verified by dNGFR and HSA markers. pNL4-3 trans-
fection was comparable between different constructs and reached 90%. pLZRS transfection was below 50% and 
therefore cells were sorted using a BD FACSAria III cell sorter.
LZRS retroviral production and transduction. Retroviral particles were produced in PhoenixA cells as 
described before50; supernatant was harvested 48 h and 72 h post-transfection. For transduction, 5 × 104 SupT1 
cells were mixed and spinoculated with 100 μ l retroviral supernatant and DOTAP as described previously50. At 
time points d2 (48 h), d4 and d7, cells were counted and stained for dNGFR expression.
HIV-1 production, Reverse Transcriptase assay and HIV-1 infection SupT1 and CEM-GFP. 
7.5 × 105 293T cells were seeded in 6 cm culture dishes in 6 ml IMDMc. Cells were transfected the next day with 5 μ g 
plasmid DNA using jetPEI as described for cell cycle analysis. Virus was harvested 48 and 72 h post-transfection 
and frozen at − 80 °C. An RT assay was performed as previously described51. For infection, 5 × 104 cells were 
mixed and spinoculated with 100 μ l viral dilution as described previously50. At the described time points, infec-
tion was quantified using a GFP or HSA marker.
Flow cytometry. Monoclonal antibodies were used to stain HSA (CD24-APC, clone M1/69, Biolegend, San 
Diego, CA) or dNGFR (NGFR-APC, clone ME20.4, Chromaprobe, Maryland Heights, MO, USA). Data were 
acquired on a Miltenyi MACSQuant® Analyzer or BD FACSCalibur flow cytometer (for cell cycle analysis) and 
analyzed with FlowJo analysis software (FlowJo LLC, Ashland, USA).
Splicing RT-qPCR. HIV-1 mRNA species were quantified 48 h after pNL4-3 transfection of 293T cells, as 
described for HIV-1 production. mRNA was isolated, DNaseI treated and converted into cDNA as described 
previously50. Primers p1-p9 combinations for quantification of spliced and unspliced mRNA were adopted 
from Houzet and colleagues52. Primer p10 was developed in-house to quantify total mRNA (see Supplement 7). 
qPCR reactions were run on a LightCycler® 480 Real-Time PCR system as described previously50. RT-qPCR data 
were generated and analyzed using the MIQE guidelines and by using qBase data analysis software53. Results 
were normalized using reference genes ubiquitin C (UBC), TATA Box Binding Protein (TBP) and tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) to correct for sample to sam-
ple variation in cDNA yield. Next, expression levels were scaled to the WT sample for each primer set in qBase. 
This allows for the comparison of the expression levels of the different target genes between WT and mutants. 
Finally, these expression levels were corrected for total HIV mRNA (eg. affected by transfection efficiency), as 
measured by primer combination 1 + 10 in our experiments. To this end, expression levels of targets measuring 
US, SS and MS mRNA were divided by the relative expression value of primer set 1 + 10 measured for that par-
ticular construct.
Western blotting. Transfected cells were lysed in 1X Laemmli buffer at 120 μ l/106 cells and sheared to reduce 
viscosity. 10 μ g of protein lysate was combined with 4X Bolt® LDS Sample Buffer (Life Technologies) and loaded 
to a Bolt™ 4–12% Bis-Tris Plus Gel and run with MES SDS Running buffer (Bolt). After gel electrophoresis, pro-
teins were transferred to a PVDF membrane, which was blocked (TBS, 5% skim milk, 0.075% Tween-20) for 4 h 
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and stained overnight at 4 °C with monoclonal antibodies against HA (1/50000; clone 2–2.2.14, Life technologies), 
FLAG (1/125000; clone M2, Sigma-Aldrich), His6 (1/2000; clone HIS.H8, Life Technologies) or β -actin (1/2500; 
clone BA3R, Life Technologies). Secondary staining was performed with HRP-linked sheep-anti-mouse antibody 
(1/2000; NA931V, GE Healthcare Life Sciences, Little Chalfont, UK). Read-out was performed with Pierce™ 
ECL Western Blotting Substrate (Life Technologies) on an ImageQuant™ LAS 4000 imager (GE Healthcare Life 
Sciences).
Prediction of HIV-1 RNA Secondary Structure by Folding analysis. The Genebee Molecular Biology 
Server21 was used to predict RNA folding of HIV-1 genomic fragment p5041–9017.
The PPfold (v.3.1.1) algorithm was used to predict HIV-1 RNA secondary structure of the full genome23. PPfold 
was run with default settings using the High Performance Computing clusters of UGent. Folding results were 
stored in cheat table (.ct) files, after which the VARNA java application (v.3.93) was applied to visualize the RNA 
secondary structures predicted by PPfold54. The NAView layout algorithm was implemented for visualization.
Calculations and statistics. RT-qPCR data were normalized using qBasePLUS software 2.0 (Biogazelle, 
Zwijnaarde, Belgium) and the resulting “calibrated normalized relative quantities” (CNRQ) values and stand-
ard errors of this value (SE CNRQ) were then further analyzed with GraphPad Prism version 5.04 (GraphPad 
Software, San Diego, California, USA). RT activity of produced HIV-1 virus was calculated from Cq values with 
Excel 2007 (Microsoft, Redmond, WA)51. GraphPad was used to calculate and plot means and standard error of 
the mean (SEM), generate data plots and perform statistical tests as described for the respective figures.
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